Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

NCT04425291 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1680

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer
Vulvar Cancer
Vaginal Cancer
CIN1
CIN2
CIN3
VaIN1
VaIN2
VaIN3
Genital Wart
VIN 1
VIN 2
VIN 3
AIS

Interventions

BIOLOGICAL: 4-valent HPV Vaccine
BIOLOGICAL: 9-valent HPV Vaccine
BIOLOGICAL: GARDASIL®

Sponsor

Shanghai Bovax Biotechnology Co., Ltd.

Collaborators

[object Object]